Cargando…
Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial
OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823356/ https://www.ncbi.nlm.nih.gov/pubmed/27029746 http://dx.doi.org/10.3802/jgo.2016.27.e25 |
_version_ | 1782425898924900352 |
---|---|
author | Terada, Keith Y. Ahn, Hyeong Jun Kessel, Bruce |
author_facet | Terada, Keith Y. Ahn, Hyeong Jun Kessel, Bruce |
author_sort | Terada, Keith Y. |
collection | PubMed |
description | OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed ovarian cancers were divided into three groups: type 1, endometrioid, clear cell, mucinous, low grade serous, and low grade adenocarcinoma/not otherwise specified (NOS); type 2, high grade serous, undifferentiated, carcinosarcoma, and high grade adenocarcinoma/NOS; and other: adenocarcinoma with grade or histology not specified, borderline tumors, granulosa cell tumors. The odds ratios for type 1, type 2, and other ovarian cancers were assessed with regard to historical information for specific risk factors. RESULTS: Ibuprofen use was associated with a decrease in risk for type 1 ovarian cancer. Tubal ligation and oral contraceptive use were associated with a decrease in risk for type 2 ovarian cancer. A history of ectopic pregnancy was associated with a decreased risk for all ovarian cancers by almost 70%. CONCLUSION: These findings support the hypothesis that carcinogenic pathways for type 1 and type 2 ovarian cancer are different and distinct. The marked reduction in all ovarian cancer risk noted with a history of ectopic pregnancy and salpingectomy implies that the fallopian tube plays a key role in carcinogenesis for both type 1 and type 2 ovarian cancer. |
format | Online Article Text |
id | pubmed-4823356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-48233562016-05-01 Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial Terada, Keith Y. Ahn, Hyeong Jun Kessel, Bruce J Gynecol Oncol Original Article OBJECTIVE: To investigate the role of previous gynecologic surgery, hormone use, and use of non-steroidal anti-inflammatory drugs on the risk of type 1 and type 2 ovarian cancer. METHODS: We utilized data collected for the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. All diagnosed ovarian cancers were divided into three groups: type 1, endometrioid, clear cell, mucinous, low grade serous, and low grade adenocarcinoma/not otherwise specified (NOS); type 2, high grade serous, undifferentiated, carcinosarcoma, and high grade adenocarcinoma/NOS; and other: adenocarcinoma with grade or histology not specified, borderline tumors, granulosa cell tumors. The odds ratios for type 1, type 2, and other ovarian cancers were assessed with regard to historical information for specific risk factors. RESULTS: Ibuprofen use was associated with a decrease in risk for type 1 ovarian cancer. Tubal ligation and oral contraceptive use were associated with a decrease in risk for type 2 ovarian cancer. A history of ectopic pregnancy was associated with a decreased risk for all ovarian cancers by almost 70%. CONCLUSION: These findings support the hypothesis that carcinogenic pathways for type 1 and type 2 ovarian cancer are different and distinct. The marked reduction in all ovarian cancer risk noted with a history of ectopic pregnancy and salpingectomy implies that the fallopian tube plays a key role in carcinogenesis for both type 1 and type 2 ovarian cancer. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016-05 2015-12-31 /pmc/articles/PMC4823356/ /pubmed/27029746 http://dx.doi.org/10.3802/jgo.2016.27.e25 Text en Copyright © 2016. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Terada, Keith Y. Ahn, Hyeong Jun Kessel, Bruce Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title | Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title_full | Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title_fullStr | Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title_full_unstemmed | Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title_short | Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
title_sort | differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823356/ https://www.ncbi.nlm.nih.gov/pubmed/27029746 http://dx.doi.org/10.3802/jgo.2016.27.e25 |
work_keys_str_mv | AT teradakeithy differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial AT ahnhyeongjun differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial AT kesselbruce differencesinriskfortype1andtype2ovariancancerinalargecancerscreeningtrial |